Month: December 2024

Functional Dyspepsia Market Expected to Experience Major Growth by 2034, According to DelveInsight | GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharma, Korea United Pharma, Daewoong

The Key Functional Dyspepsia Companies in the market include – GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharmaceutical, Korea United Pharma, Daewoong Pharmaceutical, Eisai Co., Ltd., Johnson & Johnson, Dong-A ST Co., Ltd., Astellas Pharma Inc, Materia Medica Holding, Forest Laboratories, and others.

 

The Functional Dyspepsia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Functional Dyspepsia pipeline products will significantly revolutionize the Functional Dyspepsia market dynamics.  

 

DelveInsight’s “Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Functional Dyspepsia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Functional Dyspepsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Functional Dyspepsia Market Insights

 

Some of the key facts of the Functional Dyspepsia Market Report: 

  • The Functional Dyspepsia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • Antiemetics accounted for approximately 20% of the therapeutic market in the United States in 2023.

  • At present, the only drug specifically approved for functional dyspepsia is ACOFIDE (Acotiamide), developed by Astellas Pharma and Zeria Pharmaceuticals, with approval limited to Japan.

  • The main goal in managing functional dyspepsia is to alleviate symptoms, as the condition often shows a pattern of relapses and remissions. Treatment options consist of proton pump inhibitors, H2-receptor antagonists, prokinetic agents, and antidepressants. Additionally, testing for and treating Helicobacter pylori is advised when relevant.

  • According to a research article published in April 2021, acotiamide immediate release 300 mg once daily was found to have similar efficacy and safety as acotiamide immediate release 100 mg three times daily. Throughout the course of a four-week therapy session, patients with FD-PDS showed a significant improvement in QoL.

  • Large corporations are creating possible pharmacological candidates to enhance the Functional Dyspepsia therapy situation, including Zeria, Renexxion, and others.

  • In a Korean, a study completed the Rome III questionnaire where, 7.7% had dyspepsia; postprandial distress was reported by 5.6% and EPS by 4.2%, while 27% had both PDS and EPS

  • According to AC et al., 2020, approximately 80% of individuals with dyspepsia have no structural explanation for their symptoms and have functional dyspepsia. Functional dyspepsia affects up to 16% of otherwise healthy individuals in the general population

  • Key Functional Dyspepsia Companies: GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharmaceutical, Korea United Pharma, Daewoong Pharmaceutical, Eisai Co., Ltd., Johnson & Johnson, Dong-A ST Co., Ltd., Astellas Pharma Inc, Materia Medica Holding, Forest Laboratories, and others

  • Key Functional Dyspepsia Therapies: GW679769 oral tablets, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Rabeprazole, Imonogas, Z-338, Motilitone ®, YM443, Kolofort, Itopride Hydrochloride, and others

  • The Functional Dyspepsia epidemiology based on gender analyzed that Functional Dyspepsia affects females more than males

 

Functional Dyspepsia Overview

Functional dyspepsia is a common gastrointestinal disorder characterized by persistent or recurrent symptoms of upper abdominal discomfort, bloating, early satiety, and nausea, without any identifiable structural or biochemical abnormalities. It is often classified into two subtypes: epigastric pain syndrome, which involves pain or discomfort in the upper abdomen, and postprandial distress syndrome, characterized by discomfort after meals. The exact cause of functional dyspepsia is not well understood, but it may involve factors such as impaired gastric motility, increased sensitivity of the stomach, and psychological factors. Treatment typically focuses on symptom relief through lifestyle changes, dietary modifications, and medications.

 

Get a Free sample for the Functional Dyspepsia Market Report –

https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights

 

Functional Dyspepsia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Functional Dyspepsia Epidemiology Segmentation:

The Functional Dyspepsia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Functional Dyspepsia

  • Prevalent Cases of Functional Dyspepsia by severity

  • Gender-specific Prevalence of Functional Dyspepsia

  • Diagnosed Cases of Episodic and Chronic Functional Dyspepsia

 

Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends @ Functional Dyspepsia Epidemiological Insights 

 

Functional Dyspepsia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Functional Dyspepsia market or expected to get launched during the study period. The analysis covers Functional Dyspepsia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Functional Dyspepsia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Functional Dyspepsia Therapies and Key Companies

  • GW679769 oral tablets: GlaxoSmithKline

  • DLBS2411: Dexa Medica Group

  • YM443: Astellas Pharma

  • Acotiamide hydrochloride hydrate: Zeria Pharmaceutical

  • UI05MSP015CT: Korea United Pharma

  • DWJ1252: Daewoong Pharmaceutical

  • Rabeprazole: Eisai Co., Ltd.

  • Imonogas: Johnson & Johnson

  • Z-338: Zeria Pharmaceutical

  • Motilitone ®: Dong-A ST Co., Ltd.

  • YM443: Astellas Pharma Inc

  • Kolofort: Materia Medica Holding

  • Itopride Hydrochloride: Forest Laboratories

 

 

Scope of the Functional Dyspepsia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Functional Dyspepsia Companies: GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharmaceutical, Korea United Pharma, Daewoong Pharmaceutical, Eisai Co., Ltd., Johnson & Johnson, Dong-A ST Co., Ltd., Astellas Pharma Inc, Materia Medica Holding, Forest Laboratories, and others

  • Key Functional Dyspepsia Therapies: GW679769 oral tablets, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Rabeprazole, Imonogas, Z-338, Motilitone ®, YM443, Kolofort, Itopride Hydrochloride, and others

  • Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia current marketed and Functional Dyspepsia emerging therapies

  • Functional Dyspepsia Market Dynamics:  Functional Dyspepsia market drivers and Functional Dyspepsia market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Functional Dyspepsia Unmet Needs, KOL’s views, Analyst’s views, Functional Dyspepsia Market Access and Reimbursement 

 

Discover more about therapies set to grab major Functional Dyspepsia market share @ Functional Dyspepsia Treatment Landscape

 

Table of Contents 

1. Functional Dyspepsia Market Report Introduction

2. Executive Summary for Functional Dyspepsia

3. SWOT analysis of Functional Dyspepsia

4. Functional Dyspepsia Patient Share (%) Overview at a Glance

5. Functional Dyspepsia Market Overview at a Glance

6. Functional Dyspepsia Disease Background and Overview

7. Functional Dyspepsia Epidemiology and Patient Population

8. Country-Specific Patient Population of Functional Dyspepsia 

9. Functional Dyspepsia Current Treatment and Medical Practices

10. Functional Dyspepsia Unmet Needs

11. Functional Dyspepsia Emerging Therapies

12. Functional Dyspepsia Market Outlook

13. Country-Wise Functional Dyspepsia Market Analysis (2020–2034)

14. Functional Dyspepsia Market Access and Reimbursement of Therapies

15. Functional Dyspepsia Market Drivers

16. Functional Dyspepsia Market Barriers

17.  Functional Dyspepsia Appendix

18. Functional Dyspepsia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Guarav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Functional Dyspepsia Market Expected to Experience Major Growth by 2034, According to DelveInsight | GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharma, Korea United Pharma, Daewoong

Ignite the Holiday Spirit and Experience Unforgettable Festivities at FLAME This Season

Join The Biggest Chanukah Celebration for Jewish Young Professionals in St. Pete

St. Petersburg, Florida – Get ready to light up the night and your holiday season with FLAME, the highly anticipated Chanukah celebration hosted by the Chabad Jewish Center of St. Petersburg. Join the fun on Saturday, December 28th at 8:00 PM at the trendy Savant on Second in Downtown St. Pete. This is more than just a party — it’s the ultimate gathering for Jewish young professionals across St. Pete!

Last Year’s Buzz — This Year’s Excitement!

After welcoming over 140 attendees last year, FLAME has solidified its place as the largest and most vibrant Chanukah celebration for young Jewish adults in the area. This year, it promises to be even better, with an unforgettable evening of connection, culture, and celebration.

What’s in Store at FLAME?

Enjoy a night filled with exciting activities, starting with a beautiful and meaningful Grand Menorah Lighting to mark the festival of lights. Sip and mingle at the Open Bar, and indulge in freshly made latkes at the Fresh Latke Station, featuring a variety of creative toppings ranging from classic to modern twists. Spin your way to glory in the spirited Epic Dreidel Tournament, and flaunt your most outrageous holiday sweater in the “Ugly Chanukah Sweater” Contest, where the winner will take home an exciting prize.

Secure your spot by purchasing your tickets HERE. Regular tickets are priced at $36 and can be purchased until December 24th. If you’re planning last-minute, tickets will be available for $50 at the door for late purchase. Don’t miss your chance to join the biggest Chanukah celebration for young Jewish professionals in St. Pete!

Rabbi Menachem Mendel Lebovics, host of FLAME, shares his excitement: “We are thrilled to host the 3rd annual FLAME, the most anticipated Chanukah party for young Jewish adults in St. Pete! This year, we’ve upped the game with new features like a fresh latke station and an epic dreidel competition. It’s the perfect opportunity to connect, network, and celebrate with our vibrant and growing community. It’ll be a night to remember!”

About FLAME:

FLAME is proudly brought to you by the Chabad Jewish Center of St. Petersburg, with the generous support of Jac Smith Group with Keller Williams Realty St. Pete and Otter PR. Whether you’re here to meet new friends, enjoy holiday traditions, or just have an incredible time, FLAME has something for everyone.

About Chabad:

Chabad is a place where Jews of all backgrounds and observance levels come together to connect without judgment, FLAME is a part of the Chabad young professionals Community in St. Petersburg

Don’t miss this incredible night of connection, fun, and holiday spirit. Visitthe official Chabad Young Professionals website to secure your tickets for the most exciting Chanukah event in town, and check out other upcoming events!

Media Contact
Company Name: Chabad Jewish Center
Contact Person: Gaby Bernadet
Email: Send Email
Country: United States
Website: https://www.chabadsp.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ignite the Holiday Spirit and Experience Unforgettable Festivities at FLAME This Season

Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell

The Key Fuchs Endothelial Corneal Dystrophy Companies in the maret include – ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen and ActualEye, Price Vision Group, Santen Inc., Aerie Pharmaceuticals, and others

 

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fuchs Endothelial Corneal Dystrophy Market Forecast

 

Some of the key facts of the Fuchs Endothelial Corneal Dystrophy Market Report: 

  • The Fuchs Endothelial Corneal Dystrophy market size was valued approximately USD 858 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In 2023, the United States holds the largest market size for Fuchs Endothelial Corneal Dystrophy (FECD), valued at approximately USD 394 million, surpassing the combined market sizes of the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

  • In 2023, the market size for Fuchs Endothelial Corneal Dystrophy (FECD) in Japan was approximately USD 132 million, with projections indicating growth by 2034.

  • DelveInsight’s estimates indicate that among the EU4 and the UK, Germany had the largest market for Fuchs Endothelial Corneal Dystrophy (FECD) in 2023, valued at approximately USD 88 million. Italy followed with nearly USD 67 million, while Spain had the smallest market, around USD 50 million.

  • According to DelveInsight’s analysis, in 2023, there were approximately 19 million diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM. These numbers are expected to rise throughout the forecast period (2024-2034).

  • In 2023, the United States had the highest proportion of diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) among the 7MM, accounting for about 35% of the total cases. In contrast, Spain had the lowest share, with nearly 7% of the diagnosed prevalent cases of FECD.

  • In the EU4 and the United Kingdom, the 50 to 59 age group had the highest prevalence of Fuchs Endothelial Corneal Dystrophy (FECD), with around 2.7 million cases reported in 2023. Projections suggest that these numbers will rise throughout the study period from 2020 to 2034.

  • The pipeline for FECD is dynamic, including therapies such as ripasudil (K-321), TTHX 1114, STN1010904/AE-001 (sirolimus), among others. Several of these treatments are anticipated to launch within the forecast period from 2024 to 2034.

  • Key Fuchs Endothelial Corneal Dystrophy Companies: ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen and ActualEye, Price Vision Group, Santen Inc., Aerie Pharmaceuticals, and others

  • Key Fuchs Endothelial Corneal Dystrophy Therapies:QR-504a, Ripasudil (K-321), TTHX 1114, Netarsudil, EO2002, STN1010904/AE-001 (sirolimus), Netarsudil Ophthalmic Solution, STN1010904, K-321, BSS Plus, Netarsudil Ophthalmic, and others

  • The Fuchs Endothelial Corneal Dystrophy epidemiology based on gender analyzed that females are more affected with FECD than males

  • In the age range of 50-59 years, there were roughly 2,763,146 cases in EU4 and the UK in 2021; this number is anticipated to rise during the research period of 2020–2034.

  • The Fuchs Endothelial Corneal Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fuchs Endothelial Corneal Dystrophy pipeline products will significantly revolutionize the Fuchs Endothelial Corneal Dystrophy market dynamics.

 

Fuchs Endothelial Corneal Dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive eye disease that affects the cornea, specifically the innermost layer known as the endothelium. This layer is responsible for maintaining the proper balance of fluids in the cornea, which is essential for keeping it clear and functioning correctly.

 

Get a Free sample for the Fuchs Endothelial Corneal Dystrophy Market Report:

https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market

 

Fuchs Endothelial Corneal Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation:

The Fuchs Endothelial Corneal Dystrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Fuchs Endothelial Corneal Dystrophy

  • Prevalent Cases of Fuchs Endothelial Corneal Dystrophy by severity

  • Gender-specific Prevalence of Fuchs Endothelial Corneal Dystrophy

  • Diagnosed Cases of Episodic and Chronic Fuchs Endothelial Corneal Dystrophy

 

Download the report to understand which factors are driving Fuchs Endothelial Corneal Dystrophy epidemiology trends @ Fuchs Endothelial Corneal Dystrophy Epidemiology Forecast

 

Fuchs Endothelial Corneal Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fuchs Endothelial Corneal Dystrophy market or expected to get launched during the study period. The analysis covers Fuchs Endothelial Corneal Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fuchs Endothelial Corneal Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Fuchs Endothelial Corneal Dystrophy Therapies and Key Companies

  • QR-504a: ProQR Therapeutics

  • Ripasudil (K-321): Kowa Pharmaceuticals

  • TTHX 1114: Trefoil Therapeutics

  • Netarsudil: Alcon Inc.

  • EO2002: Emmecell

  • STN1010904/AE-001 (sirolimus): Santen and ActualEye

  • Netarsudil Ophthalmic Solution: Price Vision Group

  • STN1010904: Santen Inc.

  • K-321: Kowa Research

  • BSS Plus: Alcon Research

  • Netarsudil Ophthalmic: Aerie Pharmaceuticals

 

Discover more about therapies set to grab major Fuchs Endothelial Corneal Dystrophy market share @ Fuchs Endothelial Corneal Dystrophy Treatment Market

 

Fuchs Endothelial Corneal Dystrophy Market Strengths

  • Advancements in understanding the pathophysiology and genetics of FECD, has led to identification of new treatment targets.

  • With increased disease understanding, personalized medicine for FECD patients has been developed, contributing to better management of the indication.

 

Fuchs Endothelial Corneal Dystrophy Market Opportunities

  • There is a need for drugs to treat early stage FECD patients, not yet eligible for surgery.

  • Safe and effective gene therapy is needed, as genetic factors are the major cause of FECD. Therapies using CRISPR/Cas approaches that are in the initial stages of development could be an ideal solution for the treatment eliminating the need for transplantation.

 

Scope of the Fuchs Endothelial Corneal Dystrophy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Fuchs Endothelial Corneal Dystrophy Companies: ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen and ActualEye, Price Vision Group, Santen Inc., Aerie Pharmaceuticals, and others

  • Key Fuchs Endothelial Corneal Dystrophy Therapies: QR-504a, Ripasudil (K-321), TTHX 1114, Netarsudil, EO2002, STN1010904/AE-001 (sirolimus), Netarsudil Ophthalmic Solution, STN1010904, K-321, BSS Plus, Netarsudil Ophthalmic, and others

  • Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment: Fuchs Endothelial Corneal Dystrophy current marketed and Fuchs Endothelial Corneal Dystrophy emerging therapies

  • Fuchs Endothelial Corneal Dystrophy Market Dynamics: Fuchs Endothelial Corneal Dystrophy market drivers and Fuchs Endothelial Corneal Dystrophy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Fuchs Endothelial Corneal Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Fuchs Endothelial Corneal Dystrophy Market Access and Reimbursement 

 

To know more about Fuchs Endothelial Corneal Dystrophy companies working in the treatment market, visit @ Fuchs Endothelial Corneal Dystrophy Clinical Trials and Treatment

 

Table of Contents 

1. Fuchs Endothelial Corneal Dystrophy Market Report Introduction

2. Executive Summary for Fuchs Endothelial Corneal Dystrophy

3. SWOT analysis of Fuchs Endothelial Corneal Dystrophy

4. Fuchs Endothelial Corneal Dystrophy Patient Share (%) Overview at a Glance

5. Fuchs Endothelial Corneal Dystrophy Market Overview at a Glance

6. Fuchs Endothelial Corneal Dystrophy Disease Background and Overview

7. Fuchs Endothelial Corneal Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Fuchs Endothelial Corneal Dystrophy 

9. Fuchs Endothelial Corneal Dystrophy Current Treatment and Medical Practices

10. Fuchs Endothelial Corneal Dystrophy Unmet Needs

11. Fuchs Endothelial Corneal Dystrophy Emerging Therapies

12. Fuchs Endothelial Corneal Dystrophy Market Outlook

13. Country-Wise Fuchs Endothelial Corneal Dystrophy Market Analysis (2020–2034)

14. Fuchs Endothelial Corneal Dystrophy Market Access and Reimbursement of Therapies

15. Fuchs Endothelial Corneal Dystrophy Market Drivers

16. Fuchs Endothelial Corneal Dystrophy Market Barriers

17.  Fuchs Endothelial Corneal Dystrophy Appendix

18. Fuchs Endothelial Corneal Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell

Inflammatory Myositis Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc.

“Inflammatory Myositis Market Report 2034”
The market for inflammatory myositis is influenced by several key factors, including the rising incidence of autoimmune diseases and increasing awareness of inflammatory muscle disorders. Advances in immunology and improvements in diagnostic techniques are contributing to market growth, as more cases of inflammatory myositis are identified and treated. Furthermore, growing investments in research and development for autoimmune conditions are driving innovation in this space.

DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast

Some of the key facts of the Inflammatory Myositis Market Report: 

  • The Inflammatory Myositis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • Key Inflammatory Myositis Companies: CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, and others

  • Key Inflammatory Myositis Therapies: Hizentra, PF 1801, Efgartigimod, Nipocalimab, ABC008, Daxdilimab (HZN-7734/MEDI7734/VIB7734), Enpatoran (M5049), GLPG3667, Brepocitinib (PF-06700841), ULTOMIRIS (Ravulizumab), PF-06823859 (Dazukibart), Zetomipzomib (KZR-616), and others

  • The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

  • In 2023, the US market for inflammatory myositis stood out among the seven major markets (7MM), reaching an impressive USD 301 million. This figure highlights the strong current demand and the considerable growth potential within the sector. As research and management of inflammatory myositis continue to evolve, the market is expected to expand further, with projections showing steady growth through 2034.

  • Several promising products are expected to enter the market during the 2020–2034 period, including PF-06823859, Brepocitinib, and others.

  • The therapeutic market for inflammatory myositis is projected to grow significantly, with a compound annual growth rate (CAGR) of approximately 11.7% across the 7MM. This robust expansion reflects the increasing demand for advanced treatment options and highlights the growing investment in addressing this serious condition.

  • In June 2024, Cabaletta Pharmaceuticals presented promising early clinical data from the first patient in the immune-mediated necrotizing myopathy (IMNM) cohort of their Phase I/II RESET-Myositis trial. These results, following three months of follow-up, were showcased at a satellite symposium during the EULAR 2024 Congress. The data underscored the potential of Cabaletta’s innovative approach. Patient enrollment in the RESET-Myositis trial is ongoing, with additional detailed clinical data expected later in 2024. This research represents a significant step forward in the treatment of IMNM, positioning Cabaletta at the forefront of developing transformative therapies for this complex condition.

Inflammatory Myositis Overview

Myositis refers to muscle inflammation and is commonly associated with inflammatory myopathies, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). Myopathy, a broader term, encompasses any abnormal muscle condition or disease, including myositis.

Myositis is a rare, often debilitating condition that can impact multiple organs beyond the muscles, significantly impairing the quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases where the immune system mistakenly attacks the muscles. The most common forms of inflammatory myopathy are dermatomyositis and polymyositis. Diagnosing myositis involves comprehensive laboratory testing, imaging, multidisciplinary evaluations, and sometimes genetic analysis. A thorough history and physical exam, along with routine lab tests (e.g., complete blood count, metabolic panel, muscle enzymes, thyroid-stimulating hormone), autoimmune serologies, imaging, neurologic evaluations, electromyography (EMG), nerve conduction studies, and muscle biopsy are essential for diagnosis.

The treatment approach for inflammatory myositis, which includes conditions like dermatomyositis, polymyositis, and inclusion body myositis, typically involves a combination of medications and supportive therapies tailored to the individual’s symptoms and disease severity. Common treatment options include:

– Corticosteroids: Prednisone, a high-dose corticosteroid, is often the first-line treatment to reduce inflammation and suppress the immune system. Dosage is gradually reduced to the lowest effective level.

– Immunosuppressants: Drugs like methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine may be used if corticosteroids alone are insufficient or long-term use is not advisable. These medications help suppress immune activity and inflammation.

– Biologic agents: For severe or resistant cases, biologics such as rituximab, tocilizumab, or abatacept may be considered. These target specific immune cells involved in the disease process.

– Intravenous Immunoglobulin (IVIG): For individuals with dermatomyositis or polymyositis unresponsive to other treatments, IVIG infusions can help modulate the immune system.

Treating inclusion body myositis (IBM) is particularly challenging, as it often does not respond to immunosuppressive therapies. No current treatments can stop or reverse the progression of IBM, though supportive care, physical therapy, and symptom management can improve quality of life.

There remains a significant unmet need for more effective therapies for inflammatory myositis, as current treatments with immunosuppressive drugs may not work for all patients and can lead to side effects. As a result, multiple promising therapies are in development to address this gap, with notable products such as PF-06823859, Brepocitinib, and others expected to enter the market between 2020 and 2034.

Get a Free sample for the Inflammatory Myositis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Inflammatory Myositis Epidemiology

In 2023, there were an estimated 188 thousand diagnosed prevalent cases of inflammatory myositis across the 7MM, with approximately 92 thousand of these cases occurring in the United States alone. This number is expected to rise throughout the forecast period.

The diagnosed prevalent cases were further categorized by type, with the distribution as follows: polymyositis (PM) accounted for 76 thousand cases, dermatomyositis (DM) for 84 thousand cases, and inclusion body myositis (IBM) for 27 thousand cases in the 7MM in 2023. These figures are projected to increase by 2034.

In terms of age-specific cases, inflammatory myositis in the EU4 and the UK was reported in the following age groups in 2023: 3 thousand cases in individuals aged 0–17 years, 12 thousand cases in the 18–44 years group, 25 thousand cases in the 45–64 years group, and 29 thousand cases in those aged 65 years and older.

For gender-specific diagnosed prevalent cases in Japan, there were 10 thousand cases in males and 15 thousand cases in females in 2023.

Inflammatory Myositis Epidemiology Segmentation:

The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Myositis

  • Prevalent Cases of Inflammatory Myositis by severity

  • Gender-specific Prevalence of Inflammatory Myositis

  • Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Myositis Companies

  • CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences

Inflammatory Myositis Therapies

  • Hizentra, PF 1801, Efgartigimod, Nipocalimab, ABC008, Daxdilimab (HZN-7734/MEDI7734/VIB7734), Enpatoran (M5049), GLPG3667, Brepocitinib (PF-06700841), ULTOMIRIS (Ravulizumab), PF-06823859 (Dazukibart), Zetomipzomib (KZR-616)

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Landscape

Inflammatory Myositis Market Outlook

The treatment landscape for inflammatory myositis has progressed significantly, with current approaches typically involving a combination of immunosuppressive medications, such as corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs), along with biologic agents, physical therapy, and supportive care. However, there remains a substantial unmet need for more effective, targeted therapies that offer fewer side effects. The development of novel treatments, including biologics and small molecule inhibitors, holds the potential to transform the market by providing patients with improved options.

Intravenous immunoglobulin (IVIg) has demonstrated efficacy as an initial treatment for patients with idiopathic inflammatory myopathy, with first-line IVIg monotherapy showing effectiveness in approximately 50% of patients. Treatment responses are often observed within three weeks of initiating therapy in those who respond positively. If corticosteroids, immunosuppressive agents, and IVIg do not alleviate symptoms, IV cyclophosphamide may be considered as a fourth-line treatment. However, this approach is associated with significant potential side effects and is typically reserved for patients with severe refractory conditions, such as profound muscle weakness, swallowing difficulties, and interstitial lung disease. Treatment plans must be tailored to each patient’s specific condition, disease severity, response to previous treatments, and the expertise of the healthcare provider.

As the management of inflammatory myositis continues to evolve, promising therapies are advancing through the development pipeline. These new treatments are expected to drive improvements in reimbursement strategies, physician adoption, and patient compliance. Ongoing clinical trials are investigating innovative therapies, such as PF-06823859 (Pfizer), Brepocitinib, and others, with potential market impact in the 7MM according to DelveInsight’s therapeutic market model for the forecast period.

Inflammatory Myositis Market Insights

The total market size for inflammatory myositis across the 7MM is estimated at approximately USD 589 million in 2023 and is expected to grow throughout the forecast period (2024–2034). This growth is projected at a compound annual growth rate (CAGR) of about 11.7%, driven by increased awareness of the disease and the introduction of new, emerging treatments.

Among the EU countries, Germany and Italy represented the largest market shares, with Germany accounting for USD 69 million and Italy for USD 47 million in 2023. In contrast, Spain recorded the smallest market share, with a market size of USD 21 million in the same year.

Japan’s market size stood at USD 72 million in 2023, but these dynamics are anticipated to shift during the forecast period as new treatments and market factors come into play.

Scope of the Inflammatory Myositis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Inflammatory Myositis Companies: CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, and others

  • Key Inflammatory Myositis Therapies: Hizentra, PF 1801, Efgartigimod, Nipocalimab, ABC008, Daxdilimab (HZN-7734/MEDI7734/VIB7734), Enpatoran (M5049), GLPG3667, Brepocitinib (PF-06700841), ULTOMIRIS (Ravulizumab), PF-06823859 (Dazukibart), Zetomipzomib (KZR-616), and others

  • Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies

  • Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement 

Table of Contents 

1. Inflammatory Myositis Market Report Introduction

2. Executive Summary for Inflammatory Myositis

3. SWOT analysis of Inflammatory Myositis

4. Inflammatory Myositis Patient Share (%) Overview at a Glance

5. Inflammatory Myositis Market Overview at a Glance

6. Inflammatory Myositis Disease Background and Overview

7. Inflammatory Myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Myositis 

9. Inflammatory Myositis Current Treatment and Medical Practices

10. Inflammatory Myositis Unmet Needs

11. Inflammatory Myositis Emerging Therapies

12. Inflammatory Myositis Market Outlook

13. Country-Wise Inflammatory Myositis Market Analysis (2020–2034)

14. Inflammatory Myositis Market Access and Reimbursement of Therapies

15. Inflammatory Myositis Market Drivers

16. Inflammatory Myositis Market Barriers

17.  Inflammatory Myositis Appendix

18. Inflammatory Myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Inflammatory Myositis Pipeline  

“Inflammatory Myositis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inflammatory Myositis market. A detailed picture of the Inflammatory Myositis pipeline landscape is provided, which includes the disease overview and Inflammatory Myositis treatment guidelines. 

Inflammatory Myositis Epidemiology 

DelveInsight’s ‘Inflammatory Myositis Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Myositis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Myositis Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc.

Listen live: Brenmiller Energy COO to Present at the Emerging Growth Conference on December 4, 2024, at 11:25 AM EST

Individual and institutional investors, advisors, and analysts are encouraged to attend this real-time, interactive presentation. It will highlight recent updates expected to accelerate the monetization of its projected $440 million project pipeline.

Brenmiller Energy Ltd. (Nasdaq: BNRG), a leading global provider of thermal energy storage (“TES”) solutions for industrial and utility customers, will present at the Emerging Growth Conference on Wednesday, December 4, 2024, at 11:25 AM EST.

This live, interactive online event will allow existing shareholders and the investment community to interact with the Company’s COO, Mr. Nir Brenmiller, in real time. After his presentation, and if time permits, Mr. Brenmiller may open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event, and Mr. Brenmiller will do his best to get through as many of them as possible.

Brenmiller Energy Ltd. will present for 30 minutes at 11:25 AM Eastern time. Please register using the link below to attend the Conference and receive subsequent Brenmiller Energy updates.

Register by clicking this link:https://goto.webcasts.com/starthere.jsp?ei=1677198&tp_key=9effb22694&sti=bnrg

For attendees unable to join the event live, an archived webcast will also be available on EmergingGrowth.com and the Emerging Growth YouTube Channel,http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

 

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office in a time-efficient manner.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

 

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information, visit the Company’s website at https://bren-energy.com/ and follow the Company on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in press releases that discuss the expected closing of a private placement from an existing institutional shareholder; the Company’s intent to not use its ATM facility under $3.00 per share; the Company’s efforts to improve its financial position as it executes on its commercial opportunity pipeline; the future demand for the Company’s technology and its potential pipeline of commercial opportunities valued at up to $500 million; the Company’s new HaaS business model that will produce long-term recurring revenues and aims to enhance shareholder value; and the expectation that the Company will mainly utilize third party project funding for projects under the HaaS business model. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include but are not limited to, the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; the impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 18, 2024, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release except as required by law.

 

Media contact:

Tori Bentkover

brenmillerenergy@antennagroup.com

 

Additional Disclaimers and Disclosures: This is sponsored content. Hawk Point Media Group, LLC. (HPM) has been compensated, or expects to be, to produce and distribute digital content for Brenmiller Energy Ltd. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report, and/or publication. HPM holds ZERO shares and has never owned stock in Brenmiller Energy Ltd. While HPM does not own or market shares, it is prudent to expect that those hiring HPM, including that company’s owners, employees, and affiliates, may sell some or even all of the Brenmiller Energy Ltd. shares that they own, if any, during and/or after this engagement period. Always do your own due diligence prior to investing in any publicly traded company. Forward-Looking Statements

This article contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those outlined in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 18, 2024, which is available on the SEC’s website, www.sec.gov. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release except as required by law. For Hawk Point Media Group Llc’s full disclaimer and disclosure statement,clickHERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Listen live: Brenmiller Energy COO to Present at the Emerging Growth Conference on December 4, 2024, at 11:25 AM EST

Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market

“Smoking Cessation and Nicotine Addiction Market”
DelveInsight’s “Smoking Cessation and Nicotine Addiction – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

In the market landscape of Smoking Cessation and Nicotine Addiction, an impressive surge is expected during the study period spanning 2020 to 2034, according to latest report titled  “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology and Market Forecast 2034” from DelveInsight. 

The Smoking Cessation and Nicotine Addiction market report sheds light on Smoking Cessation and Nicotine Addiction current treatment practices, upcoming drugs in the Smoking Cessation and Nicotine Addiction pipeline, market shares of individual therapies, and the anticipated trajectory of the Smoking Cessation and Nicotine Addiction market size from 2020 to 2034 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Key highlights from the Smoking Cessation and Nicotine Addiction Market Report:

  • The majority of prevalent cases of smoking cessation were estimated in the United States, followed by the EU4, the UK, and Japan, with the highest rates of tobacco use observed in the EU4 and the UK within these regions. 

  • In 2023, the smoking cessation and nicotine addiction treatment market was largest in the United States, valued at approximately USD 1,472 million, while Germany recorded the smallest market size at USD 46 million. This market is expected to grow significantly by 2034.

  • The overall market for smoking cessation and nicotine addiction treatments is forecasted to expand during the period from 2024 to 2034, driven by emerging therapies such as cytisinicline, AXS-05, and NFL-101.

  • In 2023, tobacco use in the US was more prevalent among males, with around 31,040 thousand cases, compared to 19,846 thousand cases in females.

Smoking Cessation and Nicotine Addiction Overview

Nicotine dependence is a complex condition that involves behavioral, cognitive, and physiological aspects resulting from repeated tobacco use. It is characterized by a strong craving for tobacco, difficulty in controlling its use, continued use despite negative consequences, prioritizing tobacco over other activities, increased tolerance, and withdrawal symptoms. Tobacco is the primary source of nicotine, typically consumed through smoking, chewing, or snorting, with cigarette smoking being the most common and harmful method. Contributing factors to nicotine addiction include poor enforcement of smoking bans, lack of education, insufficient motivation to quit, inadequate training among mental health professionals, and limited treatment options, particularly in underdeveloped countries. Chronic tobacco use leads to neuroadaptation and tolerance, with withdrawal symptoms like irritability, anxiety, increased appetite, and dysphoria, which are further reinforced by conditioning. These factors contribute to the significant global health burden of tobacco addiction.

Nicotine and its metabolites, such as cotinine and anabasine, can be detected in urine and blood tests to monitor compliance with withdrawal therapy or assess nicotine toxicity. Another method for measuring nicotine use is carbon monoxide (CO) levels, which correlate with cotinine levels. Several questionnaires, such as the Fagerström Test for Nicotine Dependence, the Wisconsin Inventory of Smoking Dependence and Motives, and the Smokeless Tobacco Dependence Scale, are used to assess the severity of nicotine dependence.

Effective treatment for smoking cessation and nicotine addiction typically involves a combination of pharmacotherapy, behavioral therapy, and support systems. Pharmacotherapies include nicotine replacement therapies (NRTs) like patches, gum, and lozenges, which deliver controlled doses of nicotine to reduce withdrawal symptoms and cravings. Medications such as varenicline and bupropion target neural pathways to decrease the pleasure associated with smoking and alleviate withdrawal effects. Behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, address the psychological components of addiction by helping individuals develop coping strategies, set goals, and enhance motivation to quit. Support systems, including counseling, support groups, and helplines, provide ongoing encouragement and resources, which significantly improve quit rates. Combining these approaches increases the likelihood of successful smoking cessation by addressing both the physiological and psychological aspects of nicotine dependence.

Smoking cessation and nicotine addiction epidemiology insights:

  • According to DelveInsight estimates, in 2023, the EU4 and the UK had the highest prevalence of tobacco use, with approximately 63,953 thousand cases, followed by the United States with around 50,886 thousand cases, and Japan with about 20,185 thousand cases. These numbers are projected to decline in the US, EU4, the UK, and Japan by 2034.

  • In 2023, among the EU4 and the UK, Germany had the highest prevalence of tobacco use, with approximately 18,101 thousand cases, followed by France with around 16,429 thousand cases. The UK had the lowest prevalence of tobacco use in both the EU4 and UK regions as well as the 7MM, with approximately 8,788 thousand cases.

  • Tobacco use is predominantly male-dominant. In 2023, around 59% of the prevalent tobacco use cases in the 7MM were among males, while approximately 41% were among females.

Driving Forces Behind the Smoking Cessation and Nicotine Addiction Market Growth

Increase in the patient pool, expected entry of emerging therapies will boost the Smoking Cessation and Nicotine Addiction market during the forecast period (2023–2034).

Discover the Anticipated Evolution and Growth of the Market @ Smoking Cessation and Nicotine Addiction Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

  • Smoking Cessation and Nicotine Addiction Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2034. Pioneering companies, including Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, and others, are actively engaged in developing novel drugs for potential market entry.

  • Smoking Cessation and Nicotine Addiction Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Smoking Cessation and Nicotine Addiction. Therapies such as AXS-05, Cytisinicline, NFL-101, and others are driving the Smoking Cessation and Nicotine Addiction market.

Smoking Cessation and Nicotine Addiction Market

Effective treatments for tobacco cessation include both behavioral therapies and FDA-approved medications, with a range of products and services available to support individuals trying to quit smoking. These treatments include smoking alternatives that are not specifically indicated for cessation, as well as FDA-approved pharmacotherapies, such as various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.

The US FDA has approved two smoking cessation products that do not contain nicotine: CHANTIX (varenicline tartrate) and ZYBAN (bupropion hydrochloride). Both are prescription-only tablets, and in recent years, generic versions of these drugs have entered the market. These medications are widely available in the US and Europe, while in Japan, varenicline (sold as CHAMPIX), NRT, and some off-label therapies are used for smoking cessation. However, bupropion-SR is not licensed in Japan for this purpose.

Key companies, including Achieve Life Sciences (Cytisinicline), Axsome Therapeutics (AXS-05), and NFL Biosciences (NFL-101), are currently evaluating their lead candidates in various stages of clinical development to explore their potential in treating smoking cessation and nicotine addiction.

Report Features

Details

Geography Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period

2020-2034

Smoking Cessation and Nicotine Addiction Market Size

USD XX million in 2034

Key Smoking Cessation and Nicotine Addiction Companies

Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, and others.

Leading Smoking Cessation and Nicotine Addiction Companies and Emerging Drugs: Pioneering companies such as Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, among others, are actively developing novel drugs for potential entry into the Smoking Cessation and Nicotine Addiction market.

Smoking Cessation and Nicotine Addiction Therapeutic Landscape: Key therapies identified for Smoking Cessation and Nicotine Addiction treatment include AXS-05, Cytisinicline, NFL-101, and more.

For in-depth insights, TOC, access the full report @ Smoking Cessation and Nicotine Addiction Market Outlook 2034

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market

The 3D Urology And Prostate Clinics Announce The Innovative 3D Prostate Targeted Treatment With Enhanced Precision And Effectiveness

The 3D Urology and Prostate Clinics announce the innovative 3D Prostate Targeted Treatment, offering a revolutionary approach to prostate healthcare with enhanced precision and effectiveness.

The 3D Urology and Prostate Clinics, a globally recognized medical institution specializing in prostate health, proudly introduces its groundbreaking 3D Prostate Targeted Treatment. This innovative treatment offers a non-surgical and highly effective solution for various prostate-related conditions, including prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Unlike conventional treatments, the 3D Prostate Targeted Treatment focuses on targeting and eliminating the root causes of prostate diseases, providing lasting results and minimizing the risk of recurrence. 

The 3D Prostate Targeted Treatment is a significant advancement in the field of urology. Utilizing cutting-edge diagnostic methods, the clinic’s specialists can pinpoint the exact location of the diseased tissue within the prostate. By directly targeting the affected areas, the 3D Prostate Targeted Treatment delivers natural extracts and medications with extreme precision, without harming surrounding healthy tissues. This targeted approach not only enhances the effectiveness of the treatment but also reduces side effects typically associated with conventional therapies such as surgery, radiation, or chemotherapy.

What sets the 3D Urology and Prostate Clinics apart is their comprehensive approach to prostate health, incorporating the latest advancements in 3D Targeted Therapy. This therapy involves a meticulous analysis of each patient’s condition, followed by the administration of customized medications that are delivered directly into the affected prostate tissues. The 3D Targeted Therapy is highly effective in treating chronic prostatitis, prostate tumors, and other complex prostate conditions. Patient testimonials from around the world have praised the therapy for its success in treating conditions that were previously deemed untreatable by conventional methods.

In addition to its groundbreaking treatments, the 3D Urology and Prostate Clinics is committed to providing personalized and patient-centered care. The clinic’s state-of-the-art facilities and highly experienced medical team ensure that each patient receives the highest standard of care. Furthermore, the clinic’s holistic approach to treatment includes lifestyle advice, diet recommendations, and post-treatment follow-ups to ensure lasting health benefits. The combination of advanced technology, expert care, and comprehensive treatment plans has made the 3D Urology and Prostate Clinic a global leader in prostate healthcare.

With a growing number of successful cases and satisfied patients worldwide, the 3D Urology and Prostate Clinics continue to redefine the landscape of prostate treatment. Patients from all corners of the globe, including the United States, Europe, and Australia, have traveled to the clinic in China to receive the life-changing 3D Prostate Targeted Treatment. The 3D Urology and prostate Clinic innovative therapies and commitment to excellence ensure that it remains at the forefront of prostate healthcare, offering hope and healing to patients suffering from complex prostate conditions.

About The 3D Urology and Prostate Clinics

The 3D Urology and Prostate Clinics is a leading medical facility specializing in advanced prostate treatments. The clinic is renowned for its innovative 3D Prostate Targeted Treatment, which provides effective solutions for a wide range of prostate conditions.

Media Contact
Company Name: The 3D Urology and Prostate Clinics
Contact Person: Miss Alisa Wang
Email: Send Email
Phone: +86-18673216429 (WhatsApp)
State: Hunan Province
Country: China
Website: http://www.3dprostatecure.com

Top Back Pain Specialist in San Jose, CA, Employs Advanced Techniques to Prevent Muscle Inhibition and Joint Pain

Scott Lamb, recognized by many as a top back pain specialist in San Jose, CA, is offering a cutting-edge solution to individuals suffering from chronic pain and muscle inhibition. Through Muscle Activation Techniques (MAT), Lamb is helping patients prevent and alleviate muscle weakness that can lead to joint pain and long-term dysfunction. This proactive approach is designed to address issues before they escalate, providing lasting relief and improved quality of life.

The MAT process begins with a complimentary consultation, during which patients undergo a comprehensive assessment. This includes a health history analysis, postural exam, and range of motion evaluation. “By identifying and correcting dysfunctional movement patterns early on, we can prevent muscle inhibition from leading to chronic pain,” explains Scott Lamb. This method not only addresses existing issues but also plays a crucial role in treating pain, says Scott Lamb when speaking about joint pain relief in San Jose, CA.

For those dealing with back pain, MAT offers a unique advantage. The technique works by jumpstarting muscles that have lost proper neurological connections, ensuring they function correctly to stabilize the joints. This is especially beneficial for individuals seeking hip pain therapy in San Jose, CA, as proper muscle function can reduce the strain on joints and alleviate pain.

In addition to addressing back and hip pain, MAT is effective in treating conditions like fibromyalgia. “Muscle inhibition can exacerbate symptoms of fibromyalgia, leading to increased pain and discomfort,” Lamb notes. MAT targets these underlying issues, providing a comprehensive approach to different therapies, including fibromyalgia therapy in San Jose, CA as well as many others. By restoring muscle function, MAT helps patients manage their symptoms more effectively and live a more comfortable life.

If you’re experiencing chronic pain or are concerned about muscle inhibition, MAT may be the solution you need. Early intervention is key to preventing long-term issues and maintaining joint health. To learn more about how MAT can help you, visit https://matsanjose.com. Schedule your complimentary consultation today and take control of your health with Muscle Activation Techniques.

Media Contact
Company Name: Muscle Activation San Jose
Contact Person: Scott Lamb
Email: Send Email
Phone: +1-408-766-4322
Address:1256 S Bascom Ave
City: San Jose
State: California 95128
Country: United States
Website: https://matsanjose.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Back Pain Specialist in San Jose, CA, Employs Advanced Techniques to Prevent Muscle Inhibition and Joint Pain

Top Moving Company in Hoboken, New Jersey, Ensures Smooth Transitions with Comprehensive Packing and Moving Services

Hoboken, NJ – Planning a move can be stressful, but choosing the right moving company makes all the difference. As one of the top moving services in Hoboken, New Jersey, Ample Moving is dedicated to making each relocation smooth and efficient, whether it’s a local or long-distance move. “A seamless transition requires more than just loading and unloading – it’s about careful planning, expert packing, and reliable moving services,” explains Andy Novak, strategy consultant at Ample Moving.

When it comes to pricing, timing is crucial. For those looking to save money, Andy suggests considering the off-peak season for moving. “The best time to move is during the winter months when moving costs are lower and the demand for moving companies is reduced,” he says. However, for those seeking the most comfortable moving experience, summer remains the preferred season due to favorable weather conditions. Understanding peak and off-peak times ensures customers get the best price for their move.

“Hiring a local moving company in Hoboken, NJ well in advance is crucial to securing the best movers at the right price,” Andy advises. A reputable company will be happy to provide proof of licensure, and it’s important to never settle for an unlicensed mover. At Ample Moving, the company is fully licensed and transparent about all services offered, ensuring clients receive the best possible experience.

For those unfamiliar with the moving process, understanding moving estimates is key. “There are two kinds of moving estimates: non-binding and binding,” says Andy. “A non-binding estimate is a projected cost, while a binding estimate guarantees the final price.” Both types are provided by Ample Moving, ensuring customers know exactly what to expect.

If you’re planning a move and looking for a reliable Hoboken, NJ moving company, Ample Moving offers comprehensive services, including expert packing and moving solutions. Whether you’re in need of local or long distance residential moving in Hoboken, NJ, Ample Moving provides the expertise and dedication to make your move smooth and stress-free. Visit https://amplemoving.com to get started today!

Media Contact
Company Name: Ample Moving
Contact Person: Media Relations
Email: Send Email
Phone: 1-201-721-5777
Address:9 Linden Ave
City: Jersey City
State: New Jersey 07305
Country: United States
Website: https://amplemoving.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Moving Company in Hoboken, New Jersey, Ensures Smooth Transitions with Comprehensive Packing and Moving Services

Precious Metals Mining: The Next Big Opportunity in the Face of Economic Challenges (SDRC, KGC, HYMC, BTG)

As concerns grow over global economic stability, including inflation, geopolitical tensions, and market volatility, many investors are turning to precious metals like gold and silver as a safe haven. Historically, these metals have been seen as reliable stores of value during uncertain times. As the price of gold continues to rise, driven by both economic anxieties and a shift toward alternative investments, mining companies in the precious metals sector are also seeing increased attention. While the spotlight often shines on the latest trends in tech stocks or banking, the ongoing upward movement in mining stocks presents a potentially lucrative opportunity for investors looking to hedge against economic risks and capitalize on long-term growth in the sector.

Now, let’s take a closer look at some companies that are well-positioned to take advantage of these trends and demonstrate potential for growth in the current market.

Sidney Resources Corporation (OTC: SDRC) is an innovative leader in precious metals exploration, mine development, and green technology. With a commitment to sustainability, the company aims to revolutionize traditional mining practices, implementing environmentally conscious methods that prioritize clean water, clean refining, and reduced environmental impact. Its mission is as much about creating economic value as it is about fostering a healthier world for future generations.

In September 2024, Sidney Resources announced a groundbreaking expansion of its flagship Warren District Project in Warren, Idaho, increasing its land holdings by 1,900 acres—a 500% boost to its exploration footprint. This move brings the company’s total regional control to 3,174 acres, solidifying Sidney’s dominance in an area renowned for its historic production of precious metals and rare earth elements. Among the newly acquired claims are numerous historically significant mines, including the New Era, Monitor, Summit, and Silver Monarch. These sites have a rich legacy of mineral extraction, and preliminary surface ore analysis has already revealed exceptional grades of gold, silver, and platinum group metals. Notably, assays from these expanded claims show values as high as 12.8 oz/t gold and 114 oz/t silver, underscoring the district’s immense resource potential.

The Warren District expansion not only positions Sidney Resources for long-term production but also presents significant near-term opportunities. Historical tailings from the region’s mining past are being reexamined, with early findings suggesting the potential for resource recovery that was previously overlooked. The expansion ensures Sidney’s ability to maintain control over key mineral deposits while safeguarding the district from potential acquisition by competing entities. CEO Sean-Rae Zalewski highlighted the significance of this development, describing it as “the tip of the spear” for Sidney’s growth strategy.

To complement its operational advancements, Sidney Resources recently welcomed Jim Scherrer, a highly respected industry leader, to its Board of Directors. With over 38 years of experience transforming infrastructure and driving strategic growth, Scherrer brings a wealth of expertise that will be instrumental as the company scales its operations. His leadership, combined with the proven capabilities of Sidney COO Dan Hally, will guide the company through its next phase of development. Scherrer’s influence is already evident, with plans underway for a cutting-edge milling and processing facility designed to significantly enhance the company’s processing capacity and operational efficiency.

On December 2, 2024, Sidney announced another transformative milestone: the successful raising of over $8.0 million in funding to support its ambitious expansion. This capital, supported by Board members including Jim Scherrer and Sue Maas, will drive the construction of the new facility, which is set to begin in Q2 2025 and be operational by late 2025. The facility is expected to meet soaring market demand by increasing throughput, reducing processing times, and ensuring adherence to strict environmental standards. This project represents a pivotal step in Sidney’s efforts to maximize the value of its expanded Warren District holdings.

As CEO Zalewski explained, “The confidence our investors have shown in our vision empowers us to scale our operations and leverage our resources more effectively. With this funding and the leadership of our Board, we are building the infrastructure necessary to unlock the full potential of our assets and deliver exceptional value to our shareholders.”

The significance of these developments cannot be overstated. With its expanded exploration footprint, growing control over historically productive sites, and investment in state-of-the-art facilities, Sidney Resources is positioning itself as a dominant force in the mining industry. Its focus on sustainability and innovation sets it apart in a sector increasingly shaped by environmental concerns and operational efficiency.

Investors should take note of Sidney’s unique value proposition: a combination of high-grade resources, visionary leadership, and a clear plan for scaling production. As the company moves toward its next phase of growth, SDRC remains steadfast in its mission to deliver shareholder returns while setting a new standard for responsible mining practices.

Kinross Gold Corporation (NYSE: KGC), a Canadian-based senior gold producer, continues to strengthen its position as a global leader in the mining industry. With operations spanning the United States, Brazil, Mauritania, Chile, and Canada, Kinross is focused on sustainable mining practices and disciplined financial growth, making it a solid contender in the precious metals sector.

Recently, Kinross demonstrated its commitment to growth through a key investment in Puma Exploration Inc., acquiring a 9.9% stake via a $1 million private placement. This deal, closed in October 2024, grants Kinross rights to maintain or increase its stake to 19.9% while enabling Puma to further its exploration efforts across its highly prospective gold projects in Northern New Brunswick. Puma’s assets, particularly the Williams Brook property, are situated along the Rocky Brook Millstream Fault—a geological structure linked to significant gold deposits. This partnership underscores Kinross’s strategy of leveraging promising exploration assets while supporting junior miners with aligned goals.

Beyond its investment activities, Kinross’s operational and financial results in Q3 2024 reinforce its robust standing. The company produced 564,106 gold equivalent ounces, maintaining all-in sustaining costs of $1,350 per ounce while achieving notable margin expansion to $1,501 per ounce. Strong cash flow generation remains a hallmark of Kinross’s operations, with the quarter delivering a record $414.6 million in attributable free cash flow. This allowed the company to repay $350 million in debt during the quarter, strengthening its balance sheet and positioning it well for future growth.

Kinross also declared a quarterly dividend of $0.03 per share, payable on December 12, 2024, reflecting its continued focus on shareholder returns. The company remains on track to meet its 2024 guidance for production, costs, and capital expenditures. Key development milestones during the quarter include the commissioning of the Manh Choh project, contributing to record results at Fort Knox, and advancing the Great Bear project in Ontario. The latter’s Preliminary Economic Assessment projects over 500,000 ounces of annual production at an all-in sustaining cost of approximately $800 per ounce during its first eight years, highlighting its potential as a high-margin asset.

With a disciplined approach to operational efficiency, cost control, and strategic investments in emerging opportunities, Kinross Gold Corporation continues to present a compelling story for investors seeking exposure to the gold sector.

Hycroft Mining Holding Corp. (NASDAQ: HYMC) continues to attract attention in the mining sector as it pushes forward with significant advancements at its Hycroft Mine in northern Nevada. Known as one of the largest precious metal deposits globally, the Hycroft Mine sits in a Tier-One mining jurisdiction, offering exceptional exploration potential for both gold and silver. The company is transitioning from traditional oxide heap leaching to sulfide ore processing, which is expected to unlock considerable value for shareholders.

Recent exploration efforts have focused on two emerging high-grade silver-dominant trends: Vortex and Brimstone. Hycroft’s 2024 drilling program, which expanded to 8,500 meters due to ongoing success, aims to solidify these trends and add high-grade mining opportunities to the company’s development plans. Notably, drilling results from both trends have continued to exceed expectations.

At Vortex, Hycroft recently extended mineralization approximately 100 meters west and south, while maintaining strong continuity of high-grade silver with notable gold values. Among the standout results is drill hole H24D-6001, which intercepted 124.4 meters grading 102.59 g/t silver and 0.95 g/t gold, including a spectacular interval of 8.9 meters at 475.56 g/t silver. Similarly, hole H24D-6007, designed to test the western extension of Vortex, returned 69 meters of 108.38 g/t silver and 0.57 g/t gold, with several intervals exceeding 1,400 g/t silver. These results confirm the system remains open in all directions, with additional drilling planned to define the full extent of the mineralization.

Meanwhile, at Brimstone, Hycroft is proving the continuity of its high-grade silver veins down-dip, with some of the most impressive results reported to date. Drill hole H24D-6010 returned 18.2 meters grading 1,987.35 g/t silver and 0.35 g/t gold, including multiple sub-intervals exceeding 5,000 g/t silver and a staggering 0.3-meter intercept of 20,280 g/t silver. These results underscore Brimstone’s potential as a world-class silver asset, with further drilling planned to explore extensions both up and down-dip.

Beyond exploration, Hycroft is advancing critical technical studies for sulfide ore processing. Recent metallurgical testing has shown significant improvements in gold and silver recoveries through flotation, increasing the project’s overall economic appeal. The company is also assessing whether roasting technology might provide a more cost-effective alternative to pressure oxidation (POX) for processing sulfide material.

Financially, Hycroft maintains a solid foundation, with an unrestricted cash balance of $55.8 million as of September 30, 2024. The company has successfully managed its operations with no safety incidents in over two years, earning recognition from the Nevada Mining Association for its exemplary safety record.

Diane Garrett, President and CEO of Hycroft, emphasized the company’s progress:”Our exploration efforts have yielded tremendous results, both in identifying high-grade silver trends and in advancing our technical studies. These developments are laying the groundwork for a strong future, and we remain focused on delivering value to our shareholders.”

B2Gold Corp. (NYSEAMERICAN: BTG) headquartered in Vancouver, Canada, is a prominent low-cost gold producer with active mining operations in Mali, Namibia, and the Philippines. Established in 2007, the company is also advancing the Goose Project in northern Canada, alongside other development and exploration initiatives in regions such as Colombia, Mali, and Finland. With a track record of operational growth and a focus on efficiency, B2Gold has positioned itself as a key player in the global mining industry.

In October 2024, the company bolstered its leadership by appointing Greg Barnes and Basie Maree to its Board of Directors, effective November 1, 2024. Barnes brings over 30 years of expertise in mining equity research and corporate development, while Maree contributes more than four decades of operational and project development experience in top-tier mining firms. These additions aim to strengthen the company’s operational and financial strategies as it expands its global footprint.

Operationally, B2Gold reported gold production of 180,553 ounces in Q3 2024, with year-to-date cash operating costs of $865 per ounce, aligning with annual guidance. While Fekola faced challenges such as weather disruptions and equipment issues, Masbate and Otjikoto exceeded expectations. The company also reported strong financial liquidity, with $431 million in cash as of September 30, 2024, and declared a Q4 dividend of $0.04 per share.

Looking ahead, B2Gold anticipates gold production in 2024 to be at the lower end of its guidance range of 800,000 to 870,000 ounces. Production is expected to rise in 2025 with the contribution of higher-grade ore from Fekola pits, the Fekola Regional and Underground projects, and the Goose Project, which is slated for its first gold pour in Q2 2025. Exploration continues to play a vital role, with projects such as the Gramalote Project in Colombia and the Springbok Zone in Namibia showing promising potential for long-term growth.

Through disciplined operations, robust development plans, and an ongoing commitment to shareholder returns, B2Gold remains focused on enhancing its production profile and sustaining its leadership in the global gold mining industry.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content related to SDRC. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Precious Metals Mining: The Next Big Opportunity in the Face of Economic Challenges (SDRC, KGC, HYMC, BTG)